论文部分内容阅读
目的观察岩舒注射液(复方苦参注射液)联合化疗对晚期胃癌患者生活质量的改善及安全性的影响。方法将120例晚期胃癌患者随机分为观察组和对照组,每组60例。对照组患者采用FOLFOX方案常规化疗。观察组患者在对照组化疗方案基础上,同时加用岩舒注射液15ml入0.9%氯化钠注射液250ml静滴,每天1次,10d为1个疗程。2~6个周期化疗后进行疗效评价。观察两组患者生活质量评分、卡氏评分、疼痛评估、免疫功能和不良反应。结果生活质量评分、卡氏评分:观察组疗效优于对照组,差异有统计学意义(P<0.05)。疼痛评估:观察组疼痛缓解率明显高于对照组(P<0.01)。免疫指标:治疗前两组患者四项免疫功能水平无明显差异,观察组化疗前后各指标变化差异无统计学意义(P>0.05);对照组化疗后CD3、CD4、CD4/CD8指标均较化疗前明显下降,CD8上升,差异有统计学意义(P<0.01)。两组治疗后各指标差异有统计学意义(P<0.01)。观察组患者化疗后出现的不良反应大多较对照组少且程度减轻,差异有统计学意义(P<0.05)。结论岩舒注射液配合化疗治疗晚期胃癌,能改善生活质量,缓解疼痛,增强机体免疫功能,降低化疗药物不良反应。
Objective To observe the effect of Yanshu Injection (Compound Kushen Injection) combined with chemotherapy on improving quality of life and safety of patients with advanced gastric cancer. Methods 120 patients with advanced gastric cancer were randomly divided into observation group and control group, 60 cases in each group. Patients in the control group received conventional chemotherapy with FOLFOX regimen. Observation group patients in the control group chemotherapy based on the program, while adding Yan Shu injection 15ml 0.9% sodium chloride injection 250ml intravenous infusion, once a day, 10d for a course of treatment. 2 ~ 6 cycles after chemotherapy efficacy evaluation. Quality of life scores, Karnofsky scores, pain assessment, immune function and adverse reactions were observed in both groups. Results Quality of life score and Karnofsky score: The observation group had better curative effect than the control group, the difference was statistically significant (P <0.05). Pain assessment: The pain relief rate in the observation group was significantly higher than that in the control group (P <0.01). Immune index: Before treatment, there was no significant difference in the four immunological functions between the two groups. There was no significant difference in each index between the two groups before and after chemotherapy (P> 0.05). The levels of CD3, CD4 and CD4 / CD8 in the control group were significantly higher than those in the chemotherapy group Before significantly decreased, CD8 increased, the difference was statistically significant (P <0.01). There was significant difference between the two groups after treatment (P <0.01). Adverse reactions in observation group were mostly less and lesser than those in control group after chemotherapy, the difference was statistically significant (P <0.05). Conclusion Yanshu injection combined with chemotherapy for advanced gastric cancer can improve the quality of life, relieve pain, enhance immune function and reduce adverse reactions of chemotherapy drugs.